AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27604532
Drug: Intramuscular group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular group (intramuscular injection of betamethasone and US-guided intratenosynovial isotonic saline injection)
Trial: 27604532
Drug: Intratenosynovial group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratenosynovial group (saline intramuscularly and US-guided intratenosynovial betamethasone injection)
Trial: 24565123
Drug: Ketamine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (5 mcg.kg(‐1).min(‐1)) and remifentanil (0.4 mcg.kg(‐1).min(‐1))
Trial: 24565123
Drug: Remifentanil (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.4 mcg.kg(‐1).min(‐1)) and saline solution
Trial: 21885625
Drug: Long-acting β-agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting β-agonists
Trial: 17321595
Drug: Clinical management/pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical management/pharmacotherapy
Trial: 17321595
Drug: Monthly maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly maintenance IPT/pharmacotherapy
Trial: 17321595
Drug: Monthly maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly maintenance IPT/placebo
Trial: 15204461
Drug: Electromagnetic field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electromagnetic field treatment with calcitonin and exercise
Trial: 15204461
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with calcitonin and exercise
Trial: 11355928
Drug: 60 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 daunorubicin for 3 days in combination with standard dose Ara‐C and 6‐thioguanine for induction and consolidation, followed by prolonged monthly maintenance chemotherapy for at least 1 year.
Trial: 9476677
Drug: High‐dose fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐dose fentanyl anaesthesia (group II)
Trial: 30721998
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy interventions; details on dosage and duration not available.
Trial: 30721998
Drug: Training music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training music intervention providers; details on dosage and duration not available.
Trial: 30721998
Drug: Intervention delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention delivery supervision; details on dosage and duration not available.
Trial: 30721998
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of intervention protocol adherence; details on dosage and duration not available.
Trial: 28159015
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg IC43 without adjuvant
Trial: 28159015
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg IC43 with adjuvant
Trial: 28159015
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg IC43 with adjuvant
Trial: 24444353
Drug: PEG‐IFN therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN therapy
Trial: 17013468
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg melatonin and 50 mg zinc acetate
Trial: 17013468
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg melatonin and 50 mg zinc acetate in addition to metformin
Trial: 14960215
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) for insomnia (comprising sleep hygiene, stimulus control, relaxation and cognitive therapy components)
Trial: 14960215
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) for insomnia
Trial: 10417577
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (control group)
Trial: 8706196
Drug: Pre‐induction volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐induction volume loading (12 ml x kg(‐1) Ringer's lactate)
Trial: 2194304
Drug: Hyperfractionated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiotherapy (2 x 1.2 Gy/day, five days/week, total dose 74.4 to 79.2 Gy) with simultaneous Cisplatinum (20 mg/m2 day, i.v., five days in the first and fifth week of the radiotherapy)
Trial: 157893
Drug: Vioform cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vioform cream, Locacorten‐Vioform cream, Vioform‐Hydrocortisone cream (topical application of 30 mg clioquinol each)
Trial: 157893
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of clioquinol (30 mg)
Trial: 31186189
Drug: Intervention (vaccine)
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention (vaccine) risk video
Trial: 27380904
Drug: CCTA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCTA with IV nitrate infusion
Trial: 25347938
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg ipragliflozin
Trial: 24598046
Drug: Intranasal Ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Ketamine (2 mg/kg) and Midazolam (0.5 mg/kg)
Trial: 24598046
Drug: Intranasal Ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Ketamine and Midazolam
Trial: 18841327
Drug: Weekly oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly oxaliplatin 60 mg/m(2) and 5-fluorouracil 225 mg/m(2) daily throughout radiation therapy
Trial: 9806255
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg Cetrorelix
Trial: 9806255
Drug: 0.50 mg
RxNorm normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 mg Cetrorelix
Trial: 9806255
Drug: 1.00 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.00 mg Cetrorelix
Trial: 7700286
Drug: No myelosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No myelosuppressive therapy (Control)
Trial: 29778918
Drug: SHUTi (internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHUTi (internet-based cognitive behavioral therapy for insomnia)
Trial: 24237188
Drug: PC-18 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PC-18 at 37.5 mg by mouth two times per day (PO bid) for 3 weeks (induction phase)
Trial: 24237188
Drug: PC-18 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PC-18 at the same dose (37.5 mg PO bid) during the maintenance phase
Trial: 20958145
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (CT) with allopurinol (100‐200 mg/day) and citrate preparation (3 g/day) for 12 weeks
Trial: 20958145
Drug: Allopurinol monotherapy
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol monotherapy (MT) (100‐200 mg/day) for 12 weeks
Trial: 20958145
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (CT) with allopurinol and citrate preparation
Trial: 20958145
Drug: Allopurinol monotherapy
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol monotherapy (MT)
Trial: 17145540
Drug: Three-Dimensional Conformal
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-Dimensional Conformal Radiation Therapy (3D-CRT)
Trial: 12932071
Drug: Propofol 15
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 15 mg (1.5 mL) in Group P
Trial: 12932071
Drug: Midazolam 1
RxNorm normalized name: midazolam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 1 mg in Group M1
Trial: 12932071
Drug: Midazolam 2
RxNorm normalized name: midazolam 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 2 mg in Group M2
Trial: 12932071
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg in Group O
Trial: 26053341
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (endotracheal intubation during mechanical ventilation)
Trial: 23782463
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg) added to treatment as usual
Trial: 23782463
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg OD, increased to 40 mg after 4 weeks) added to treatment as usual
Trial: 23782463
Drug: Ondansetron and
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron and Simvastatin added to treatment as usual
Trial: 20230405
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) 3 mg/m² on days 1, 3, and 5 (arm A)
Trial: 20230405
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) 6 mg/m² on day 1 and 3 mg/m² on day 8 (arm B)
Trial: 18986292
Drug: Blinding of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinding of clinical trial participants and study drug assignment
Trial: 16902792
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of methylprednisolone injected intramuscularly
Trial: 9017565
Drug: Histories of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histories of violence, use of drugs, or demographic characteristics
Trial: 1705921
Drug: Future oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Future oriented hypnotic imagery
Trial: 18587620
Drug: Bupropion (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (150 mg SR, BID)
Trial: 16998453
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (3 x 1000 mg/day for 8 days)
Trial: 16998453
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 x 50 mg/day of glucose for 8 days)
Trial: 15151735
Drug: Oxytocin 10
RxNorm normalized name: oxytocin 10 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin 10 IU IV infusion
Trial: 11283917
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg zoledronic acid
Trial: 11283917
Drug: 4.0 mg
RxNorm normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 mg zoledronic acid
Trial: 11346861
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg pamidronate
Trial: 11283917
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg zoledronic acid
Trial: 11283917
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (including 2.0 mg and 4.0 mg zoledronic acid, and 90 mg pamidronate)
Trial: 9276357
Drug: Radiation plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation plus immediate LHRH agonist (androgen suppression)
Trial: 2885122
Drug: All beta-adrenoceptor
RxNorm normalized name: all-trans-beta-Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All beta-adrenoceptor antagonists (except pindolol)
Trial: 2885122
Drug: All beta-adrenoceptor
RxNorm normalized name: all-trans-beta-Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All beta-adrenoceptor antagonists
Trial: 30612482
Drug: Betamethasone (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (intramuscular injection of 12 mg in two doses with an interval of 24 hours)
Trial: 30306310
Drug: HPV vaccination
RxNorm normalized name: HPV-16 trojan peptide vaccine
DrugBank: HPV-16 trojan peptide vaccine (DB17496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccination post treatment
Trial: 27753551
Drug: Sub-dissociative dose
RxNorm normalized name: DAB(SUB 389)IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-dissociative dose (0.2 mg/kg) of IV ketamine
Trial: 20142823
Drug: Multivitamin and
RxNorm normalized name: Multivitamin and Minerals Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin and mineral supplement (MMS)
Trial: 19329405
Drug: Calcium 162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 162 mg
Trial: 15996074
Drug: DHEA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA supplementation (50 mg/day)
Trial: 10233206
Drug: Modified release
RxNorm normalized name: MODIFIED RELEASE CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified release verapamil p.o. (240 mg) administered in the morning (08:00 h)
Trial: 10233206
Drug: Modified release
RxNorm normalized name: MODIFIED RELEASE CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified release verapamil p.o. (240 mg) administered in the evening (20:00 h)
Trial: 10233206
Drug: Deuterated verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deuterated verapamil i.v. (10 mg) administered in the morning
Trial: 10233206
Drug: Deuterated verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deuterated verapamil i.v. (10 mg) administered in the evening
Trial: 1924426
Drug: 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg E5
Trial: 1924426
Drug: 7.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/kg E5
Trial: 1924426
Drug: E5 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5 (2.5 mg/kg and 7.5 mg/kg)
Trial: 24445092
Drug: 2.4 mL
RxNorm normalized name: 2.4 ML Imfinzi 50 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 mL contrast agent
Trial: 24445092
Drug: 4.8 mL
RxNorm normalized name: Elyxyb 120 MG in 4.8 mL Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.8 mL contrast agent
Trial: 24445092
Drug: 1.2 mL
RxNorm normalized name: Mozobil 24 MG in 1.2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mL contrast agent
Trial: 20447259
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) combined with metronidazole (MTZ) 400 mg 3 x per day and amoxicillin (AMX) 500 mg 3 x per day for 14 days
Trial: 15990456
Drug: pegylated IFN
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegylated IFN α‐2b plus a standard or weight‐based dose of ribavirin
Trial: 7725889
Drug: Nefopam hydrochloride
RxNorm normalized name: nefopam hydrochloride
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam hydrochloride (20 mg) in group A
Trial: 7725889
Drug: Meperidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (50 mg) in group A
Trial: 7725889
Drug: Nefopam hydrochloride
RxNorm normalized name: nefopam hydrochloride
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam hydrochloride (10 mg) in group B
Trial: 7725889
Drug: Nefopam hydrochloride
RxNorm normalized name: nefopam hydrochloride
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam hydrochloride (20 mg) in group C
Trial: 1904749
Drug: Racemic ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Racemic ibuprofen 400 mg
Trial: 1904749
Drug: Racemic ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Racemic ibuprofen 1200 mg
Trial: 6100880
Drug: enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 20 mg once-a-day
Trial: 24170766
Drug: 2-hour suspension
RxNorm normalized name: dextroamphetamine 2 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hour suspension of basal insulin
Trial: 20647511
Drug: Standard aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard aqueous cream
Trial: 10528035
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg daily for 52 weeks
Trial: 9495581
Drug: Ranitidine 100
RxNorm normalized name: ranitidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 100 mg i.v. twice a day for five days
Trial: 7803739
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of protamine (Group I)
Trial: 24357473
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein intake (<0.8 g/(kg · d))
Trial: 24357473
Drug: Moderate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate protein intake (0.8-<1.0 g/(kg · d))
Trial: 24357473
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein intake (1.0-1.2 g/(kg · d))
Trial: 12486283
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose 6‐methylprednisolone
Trial: 8679359
Drug: ondansetron with
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ondansetron with dexamethasone (4 mg and 8 mg, respectively)
Trial: 21811829
Drug: 300 ml
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ml warm water instillation (30 °C)
Trial: 21344803
Drug: Intratympanic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic dexamethasone injection (ITDI), administered once every week for a maximum of three sessions
Trial: 15643512
Drug: Paclitaxel (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (70 mg/m2), gemcitabine (1000 mg/m2), and cisplatin (35 mg/m2) on days 1 and 8 every 3 weeks (GCP)
Trial: 15643512
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m2 on days 1, 8, 15) and cisplatin (70 mg/m2 on day 2 every 4 weeks (GC)
Trial: 7867444
Drug: HD‐Ara‐C (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD‐Ara‐C (1.0 g/m2)
Trial: 7867444
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no HD‐Ara‐C therapy)
Trial: 31282394
Drug: Spinal decompression
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal decompression therapy (SDT) with core stabilization exercises (CSE)
Trial: 31300012
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume ventilation (6 mL/kg) in high P/F subgroup (> 150 mmHg)
Trial: 31300012
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume ventilation (6 mL/kg) in low P/F subgroup (≤ 150 mmHg)
Trial: 25906559
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) combined with transperineal injection of 200 IU BTX-A
Trial: 25906559
Drug: Transperineal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transperineal injection of 200 IU BTX-A
Trial: 24143017
Drug: Coarse CAPs
RxNorm normalized name: silica, trimethylsilyl capped
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coarse CAPs (200 µg/m(3))
Trial: 24143017
Drug: Fine CAPs
RxNorm normalized name: silica, trimethylsilyl capped
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fine CAPs (250 µg/m(3))
Trial: 19664769
Drug: Meperidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (50 mg)
Trial: 19664769
Drug: Valethamate bromide
RxNorm normalized name: valethamate bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valethamate bromide (16 mg)
Trial: 9417487
Drug: Parenteral selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral selenium supplementation (week 1: twice 500 micrograms daily, week 2: once 500 micrograms, week 3: three times 100 micrograms sodium selenite)
Trial: 9417487
Drug: Parenteral selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral selenium supplementation
Trial: 7679737
Drug: Naltrexone (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (12.5 mg)
Trial: 26135853
Drug: Naltrexone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (25 mg)